Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerold Schuler

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitorsAlvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.
Gut|April 16, 2022
Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitisCaroline Voskens, Diane Stoica, Marita Rosenberg, et al.
Blood|August 21, 2013
Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting TregAndreas S Baur, Manfred B Lutz, Stephan Schierer, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 2005
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)Ralf G Meyer, Cedrik M Britten, Ulrike Siepmann, et al.
British Journal of Cancer|February 14, 2018
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsMarkus Hecht, Friedegund Meier, Lisa Zimmer, et al.
Oncotarget|October 6, 2017
Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory proteinSonja I Buschow, Matteo Ramazzotti, Inge M J Reinieren-Beeren, et al.
Iscience|December 9, 2025
Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM)Halime Kalkavan, Max E Scheulen, Eckhart Kämpgen, et al.
Cell Metabolism|March 5, 2015
Cutaneous Na+ storage strengthens the antimicrobial barrier function of the skin and boosts macrophage-driven host defenseJonathan Jantsch, Valentin Schatz, Diana Friedrich, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyLisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitorsAlvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.
Gut|April 16, 2022
Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitisCaroline Voskens, Diane Stoica, Marita Rosenberg, et al.
Blood|August 21, 2013
Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting TregAndreas S Baur, Manfred B Lutz, Stephan Schierer, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 2005
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)Ralf G Meyer, Cedrik M Britten, Ulrike Siepmann, et al.
British Journal of Cancer|February 14, 2018
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsMarkus Hecht, Friedegund Meier, Lisa Zimmer, et al.
Oncotarget|October 6, 2017
Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory proteinSonja I Buschow, Matteo Ramazzotti, Inge M J Reinieren-Beeren, et al.
Iscience|December 9, 2025
Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM)Halime Kalkavan, Max E Scheulen, Eckhart Kämpgen, et al.
Cell Metabolism|March 5, 2015
Cutaneous Na+ storage strengthens the antimicrobial barrier function of the skin and boosts macrophage-driven host defenseJonathan Jantsch, Valentin Schatz, Diana Friedrich, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyLisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
Pageof 19